Background/aim: Methionine addiction, a fundamental and general hallmark of cancer, is due to the excess use of methionine for transmethylation, and is described as the Hoffman-effect. Methionine-addicted cancer cells can revert at low frequency to methionine independence when selected under methionine-restriction. We report here that highly-malignant methionine-addicted H460 human lung-cancer cells, when selected for methionine independence, have greatly-reduced tumorigenic potential.

Materials And Methods: Methionine-addicted H460 parental cancer cells and methionine-independent revertant H460-R1 cells were injected in nude mice subcutaneously.

Results: When the parental H460 methionine-addicted cells were injected in nude mice at 2.5×10, 1×10 and 5×10, the cells could form tumors. In contrast, the H460-R1 methionine-independent revertant cells could not form tumors when the above-listed cell numbers were injected in nude mice.

Conclusion: There is a tight linkage between methionine addiction and malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14815DOI Listing

Publication Analysis

Top Keywords

methionine addiction
12
methionine independence
12
injected nude
12
cells
8
lung-cancer cells
8
cancer cells
8
methionine-addicted h460
8
methionine-independent revertant
8
cells injected
8
nude mice
8

Similar Publications

Objective: Many cancer cells depend on exogenous methionine for proliferation, whereas non-tumorigenic cells can divide in media supplemented with the metabolic precursor homocysteine. This phenomenon is known as methionine dependence of cancer or methionine addiction. The underlying mechanisms driving this cancer-specific metabolic addiction are poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • The study explored the effectiveness of rMETase in combination with gemcitabine for treating advanced soft-tissue sarcomas, particularly focusing on HT1080 fibrosarcoma cells and gemcitabine-resistant cells that showed elevated c-MYC levels.
  • Results indicated that rMETase enhanced the cytotoxic effects of gemcitabine on fibrosarcoma cells, but not on normal fibroblasts, suggesting a targeted approach could be beneficial for treating resistant sarcoma types.
  • Overall, rMETase shows potential as an effective therapy for overcoming gemcitabine resistance in sarcoma, indicating it could be a promising option in future clinical applications.
View Article and Find Full Text PDF

Background/aim: Ifosfamide is used clinically with doxorubicin as first-line chemotherapy for soft-tissue sarcoma. However, ifosfamide efficacy for soft-tissue sarcoma is limited due to frequent occurence of ifosfamide resistance and thus more effective therapy is needed. The present study aimed to determine the synergy of recombinant methioninase (rMETase) plus ifosfamide against HT1080 human fibrosarcoma cells in vitro.

View Article and Find Full Text PDF

Background/aim: Methionine addiction, known as the Hoffman effect, makes cancer cells more sensitive to methionine restriction than normal cells. However, the long-term effects of methionine restriction on cancer and normal cells have not been thoroughly studied.

Materials And Methods: HCT-116 human colorectal-cancer cells and Hs27 normal skin fibroblasts were treated with 0-8 U/ml of recombinant methioninase (rMETase) for 12 days.

View Article and Find Full Text PDF

Background/aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim of the present study was to demonstrate the synergy of the combination of recombinant methioninase (rMETase) and ivermectin to eradicate human pancreatic cancer cells in vitro.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!